Liposomal Nanocarriers for NSAIDs and Phytochemicals: Potential in Anti-inflammatory Therapy
Inflammation plays a crucial role in various acute and chronic diseases, necessitating effective drug delivery systems to enhance therapeutic outcomes. Conventional anti-inflammatory drugs, including nonsteroidal anti-inflammatory drugs (NSAIDs) and natural bioactive compounds, often suffer from poor solubility, low bioavailability, and systemic side effects. Liposomal nanocarriers have emerged as a promising strategy for targeted and controlled drug delivery, improving drug stability, bioavailability, and therapeutic efficacy while minimizing adverse effects. This review explores the fundamentals of liposomal drug delivery systems, their advantages in anti-inflammatory therapy, and the latest advancements in liposomal formulations of NSAIDs and natural anti-inflammatory agents such as curcumin. Furthermore, we discuss the mechanisms of drug release, pharmacokinetic improvements, and the challenges associated with liposomal drug development, including formulation stability and regulatory considerations.
Keywords: Liposomal drug delivery, anti-inflammatory therapy, nanocarriers, NSAIDs, curcumin, controlled drug release, pharmacokinetics, targeted drug delivery, inflammation management, nanomedicine.
